Skip to main content
. 2020 Aug 14;12(8):2283. doi: 10.3390/cancers12082283

Table 3.

Pembrolizumab activity.

Complete Response 0/13 (0%)
Partial Response 0/13 (0%)
Stable Disease 4/13 (31%)
Disease Control Rate 4/13 (31%)
Progression Disease 9/13 (69%)
mPFS 2.2 months (95% CI 1.6–2.8)
6 month-PFS 23%
mOS 5.6 months (95% CI 0.1–11.9)
12 month-OS 38%

PFS: progression-free survival; OS: overall survival.